Evaluation of Ischemia Modified Albumin Levels and Carotid Intima Media Thickness in Patients with Systemic Lupus Eythematosus

Sami Küçükşen 1, Aysun Toker 2 * , Adem Küçük 3, Ender Salbaş 1, Ramazan Uçar 4, Mehmet Kayrak 5, Recep Tunç 3
More Detail
1 Necmettin Erbakan University, Meram Medical Faculty, Department of Physical Medicine and Rehabilitation
2 Necmettin Erbakan University, Meram Medical Faculty, Department of Biochemistry
3 Necmettin Erbakan University, Meram Medical Faculty, Department of Rheumatology
4 Necmettin Erbakan University, Meram Medical Faculty, Departmant of Internal Medicine
5 Necmettin Erbakan University, Meram Medical Faculty, Department of Cardiology
* Corresponding Author
EUR J BASIC MED SCI, Volume 4, Issue 4, pp. 77-82. https://doi.org/10.15197/sabad.2.4.14
OPEN ACCESS
Download Full Text (PDF)

ABSTRACT

Systemic lupus erythematosus (SLE) is a major cause of cardiovascular mortality and morbidity associated with early atherosclerosis. Carotid intima-media thickness (CIMT) is one of the early markers of atherosclerosis. Oxidative stress plays an important role in pathophysiologic mechanisms of SLE. Ischemia modified albumin (IMA) and total oxidant status (TOS) have been associated with oxidative stress in several diseases. In our study we aimed to investigate the relationship between serum IMA and TOS levels with CIMT in patients with SLE and to compare these with control group values. In our study, 60 SLE patients diagnosed according to the American College of Rheumatology (ACR) criteria and 35 healthy controls were included. Serum IMA levels were measured by manually spectrophotometric method. Increased serum TOS and IMA levels and CIMT were found in patients with SLE when compared with control group (p< 0.05). However, we could not find any significant correlation between serum TOS and IMA levels with CIMT values in patient group (p> 0.05). Our results suggest that serum levels of IMA and TOS increase in SLE. However lack of association between the tested parameters suggests that further researches are needed.
Keywords: ischemia modified albumin, systemic lupus erythematosus, carotid intima media thickness, total oxidant status

CITATION

Küçükşen S, Toker A, Küçük A, Salbaş E, Uçar R, Kayrak M, et al. Evaluation of Ischemia Modified Albumin Levels and Carotid Intima Media Thickness in Patients with Systemic Lupus Eythematosus. Eur J Basic Med Sci. 2014;4(4):77-82. https://doi.org/10.15197/sabad.2.4.14

REFERENCES

  • Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:338–46.
  • Goldberg RJ, Urowitz MB, Ibanez D, Nikpour M, Gladman DD. Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. Journal Rheumatol 2009;36:2454–61.
  • Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003;62:1071–7.
  • Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331–7.
  • Tyrrell PN, Beyene J, Feldman BM, et al. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2010;30:1014e26.
  • Wu T, Xie C, Han J, et al. Metabolic disturbances associated with systemic lupus erythematosus. PLoS One 2012;7(6):e37210.
  • Bae SC, Kim SJ, Sung MK. Impaired antioxidant status and decreased dietary intake of antioxidants in patients with systemic lupus erythematosus. Rheumatol Int 2002,22:238–43.
  • Suwannaroj S, Lagoo A, Keisler D, McMurray RW. Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus 2001;10:258–65.
  • Bahrehmand F, Vaisi-Raygani A, Kiani A, et al. Matrix metalloproteinase 9 polymorphisms and systemic lupus erythematosus: correlation with systemic inflammatory markers and oxidative stress. Lupus 2014 Nov 21. pii: 0961203314559085.
  • Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 2001;268:42–7.
  • Roy D, Quiles J, Gaze DC, et al. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006;92:113–4.
  • Turkmen K, Tonbul HZ, Toker A, et al. The relationship between oxidative stress, inflammation, and atherosclerosis in renal transplant and end-stage renal disease patients. Ren Fail 2012;34(10):1229-37.
  • Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
  • Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630–40.
  • Galindo M, Chung L, Crockett SD, et al. Coronary artery diease in patients with systemic lupus erythematosus. Nat Clin Practice Rheumatol 2005;1:55–9.
  • Funakubo Asanuma Y. Accelerated atherosclerosis and inflammation in systemic lupus erythematosus. Nihon Rinsho Meneki Gakkai Kaishi 2012;35(6):470–80.
  • Bruce IN, Urowitz MB, Gladman DD, et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003;48:3159–67.
  • Sacre K, Escoubet B, Pasquet B, et al. Increased arterial stiffness in systemic lupus erytematosus (SLE) patients at low risk for cardiovascular disease: a cross-sectional controlled study. PLos One 2014;109(4);e94511.
  • Gómez-Zumaquero JM, Tinahones FJ, De Ramón E, et al. Association of biological markers of activity of systemic lupus erythematosus with levels of anti-oxidized lowdensity lipoprotein antibodies. Rheumatology (Oxford) 2004;43:510–3.
  • Manzi S, Selzer F, Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42(1):51–60.
  • Kao AH, Lertratanakul A, Elliott JR, et al. Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus. Am J Cardiol 2013;112:1025e32.
  • Jung JY, Koh BR, Bae CB, Kim HA, Suh CH. Carotid subclinical atherosclerosis is associated with disease activity but not vitamin D in Korean systemiclupus erythematosus. Lupus 2014;23(14):1517-22.
  • Ammirati E, Bozzolo EP, Contri R, et al. Cardiometabolic and immune factors associated with increased common carotid artery intima–media thickness and cardiovascular disease in patients with systemic lupus erythematosus. Nutr Metab Cardiovasc Dis 2014;24(7):751-9.
  • Sincer İ, Kurtoğlu E, Yılmaz Çoşkun F, et al. Association between serum total antioxidant status and flow-mediated dilation in patients with systemic lupus erythematosus: an observational study. Anatol J Cardiol 2015. doi: 10.5152/akd.2015.5764.
  • Oates JC. The biology of reactive intermediates in systemic lupus erythematosus. Autoimmunity 2010;43:56–63.
  • Shah D, Kiran R, Wanchu A, Bhatnagar A. Oxidative stress in systemic lupus erythematosus: relationship to Th1 cytokine and disease activity. Immunol Lett 2010;129:7–12.
  • Taysi S, Gul M, Sari RA, Akcay F, Bakan N. Serum oxidant/antioxidant status of patients with systemic lupus erythematosus. Clin Chem Lab Med 2002;40:684–8.
  • Ghaly MS, Ghattas MH, Labib SM. Association of catalase gene polymorphisms with catalase activity and susceptibility to systemic lupus erythematosus in the Suez Canal area, Egypt. Lupus 2012;21(11):1244-9.
  • Mansour RB, Lassoued S, Gargouri B, et al. Increased levels of autoantibodies against catalase and superoxide dismutase associated with oxidative stress in patients with rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatol 2008;37:103–8.
  • Ben Mansour R, Lassoued S, Elgaied A, et al. Enhanced reactivity to malondialdehyde-modified proteins by systemic lupus erythematosus autoantibodies. Scand J Rheumatol 2010;39:247–53.
  • Wang G, Pierangeli SS, Papalardo E, Ansari GA, Khan MF. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum 2010;62(7):2064–72.
  • Sbarouni E, Georgiadou P, Kremastinos DT, Voudris V. Ischemia modified albumin: Is this marker of ischemia ready for prime time use? Hellenic J Cardiol 2008;49:260–6.
  • Lippi G, Montagnana M, Guidi GC. Albumin cobalt binding and ischemia modified albumin generation: An endogenous response to ischemia? Int J Cardiol 2006;108:410–1.
  • Leitemperguer MR, Tatsch E, Kober H, et al. Assessment of ischemia-modified albumin levels in patients with rheumatoid arthritis. Clin Lab 2014;60(6):1065-70.
  • Toker A, Karatas Z, Altın H, et al. Evaluation of serum ischemia modified albumin levels in acute rheumatic fever before and after therapy. Indian J Pediatr 2014;81(2):120-5.
  • Ma SG, Wei CL, Hong B, et al. Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease. Clinics (Sao Paulo) 2011,66:1677–80.
  • Toker A, Kucuksen S, Kucuk A, Cicekler H. Serum ischemiamodified albumin and malondialdehyde levels and superoxide dismutase activity in patients with fibromyalgia. Clin Lab 2014;60(10):1609-15.
  • Capkin E, Karkucak M, Kola M, et al. Ischemia-modified albumin (IMA): a novel marker of vascular involvement in Behçet’s disease? Joint Bone Spine 2015;82(1):68-9.